Halozyme Therapeutics, Inc.
Common Stock · USD · NASDAQ
Price
$68.21
Cap
—
Earnings
—
30d Trend
+8.6%
40% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 61×Macro 0.99 (−1%)=60
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Halozyme Therapeutics, Inc. at 60/100 — a STRONG reading on the Brain47 Signal. The strongest factor is quality at 76/100. I classify this as a defensive position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+10.5%
3 MONTHS
-0.7%
12 MONTHS
—
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Quality (76) and Technical (57) are the primary strengths. I note that fundamentals is the weakest area at 35/100 — this warrants monitoring. Historical volatility is moderate at 40%. I classify this as a defensive holding — stability characteristics and high business quality provide portfolio ballast.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.